Arcellx, Inc.
Engineering controllable cell therapies for cancer and autoimmune diseases.
ACLX | NDAQ
Overview
Corporate Details
- ISIN(s):
- US03940C1009
- LEI:
- Country:
- United States of America
- Address:
- 800 BRIDGE PARKWAY, 94065 REDWOOD CITY
- Website:
- https://www.arcellx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative immunotherapies for patients with cancer and autoimmune diseases. The company is focused on reimagining cell therapy by leveraging its proprietary D-Domain technology. This technology is the foundation for its two key platforms: ddCAR, which aims to create more controllable and effective CAR-T therapies, and ARC-SparX, a platform for adaptable and universal cell therapies. Arcellx's mission is to advance humanity by engineering treatments that are safer, more effective, and broadly accessible, with a significant focus on treating conditions like relapsed or refractory multiple myeloma.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Arcellx, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Arcellx, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Arcellx, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
